Amarin, FDA Agree To Allow ‘Truthful, Non-Misleading’ Off-Label Speech About Drug
WASHINGTON, D.C. — Amarin Pharma Inc. and the Food and Drug Administration on March 8 sent a federal judge a proposed settlement in which the FDA agrees that Amarin may engage...To view the full article, register now.
Already a subscriber? Click here to view full article